EyeTechCare secures third round of funding for EyeOP1

Article

EyeTechCare has secured ?10 million in a third round of funding for two international clinical trials for the EyeOP1 glaucoma treatment.

EyeTechCare has secured €10 million in a third round of funding for two international clinical trials for the EyeOP1 glaucoma treatment.

The firm, which develops non-invasive therapeutic medical devices for the ophthalmology market, plans to use the funds to complete the EyeMUST 2 international trial. The results are due to be published in 2014 and the company will be able to fund the FDA registration process.

Mr Bernard Chauvin, MD of EyeTechCare and private investor, stated, "The simplicity of EyeOP1 comes from an uncomplicated yet brilliant idea: the use of ultrasound to treat glaucoma. Beyond the complex technical constraints, which have been incredibly well managed, there is a team with the desire to achieve their goal of helping patients."

"Quite simply, the results are there," continued Mr Chauvin, "I am proud to be associated with what is real therapeutic progress, particularly as it fits so well with my vocation as a doctor and an entrepreneur."

Alex Perouse, co-head of venture capital activity at Omnes Capital, added, "We've been excited by EyeTechCare's market positioning right from the start. The arrival of this new investor will support the growth of the business. The company's prospects for development are very encouraging and the team in place has always been able to meet its self-imposed deadlines."

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.